RAPID ACCESS TO PREVENTIVE INTERVENTION DEVELOPMENT - RAPID - ADDENDUM
Release Date: July 13, 2000
NOTICE: CA-00-021
National Cancer Institute
Investigators are hereby notified that the receipt date for requests for
RAPID resources has been changed to November 21, 2000. Investigators are
further notified that the website for the RAPID initiative has been updated,
see http://dcp.nci.nih.gov/CB/.
The Rapid Access to Preventive Intervention Development (RAPID) makes
available to academic investigators the preclinical and early clinical drug
development contract resources of NCI’s Division of Cancer Prevention. The
goal of RAPID is the rapid movement of novel molecules and concepts from the
laboratory to the clinic for clinical trials of efficacy. RAPID will assist
investigators who submit successful requests by providing any (or all) of the
pre-clinical and phase 1 clinical developmental requirements for phase 2
clinical efficacy trials. These include, for example, preclinical
pharmacology, toxicology, and efficacy studies, bulk supply, GMP
manufacturing, and formulation, and regulatory and IND support and phase 1
clinical studies.
INQUIRIES:
Inquiries are encouraged, and the opportunity to clarify issues or answer
questions is welcome. Inquiries may be directed to:
RAPID
c/o James A. Crowell, Ph.D.
Division of Cancer Prevention, NCI
Executive Plaza North, Suite 200B
6130 Executive Blvd., Rockville, MD 20852 (overnight mail)
9000 Rockville Pike, Bethesda, MD 20892 (regular mail)
Telephone (301) 496-8563
Fax (301) 402-0553
email inquiries to: jc94h@nih.gov
Weekly TOC for this Announcement
NIH Funding Opportunities and Notices
|
|
|
|
Department of Health and Human Services (HHS)
|
|
|
|
NIH... Turning Discovery Into Health®
|